Third Harmonic Bio, Inc. Common Stock
THRD US88427A1079
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
Annual Performance 1
| 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|
| -78% | 164% | -8% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Conner Edward R. CMO |
15.00 USD |
2,117 Sold |
31,755 USD |
08/11/2024 | 08/11/2024 |
| Conner Edward R. CMO |
15.00 USD |
2,673 Sold |
40,095 USD |
28/10/2024 | 28/10/2024 |
| Conner Edward R. CMO |
15.00 USD |
4,790 Sold |
71,850 USD |
19/09/2024 | 19/09/2024 |
| Person Julie SR OFF |
14.29 USD |
9,497 Sold |
135,685 USD |
18/09/2024 | 19/09/2024 |
| Person Julie SR OFF |
14.00 USD |
503 Sold |
7,042 USD |
18/09/2024 | 18/09/2024 |
| Person Julie SR OFF |
12.46 USD |
10,000 Sold |
124,569 USD |
26/06/2024 | 26/06/2024 |
| Dittman Jennifer SR OFF |
14.17 USD |
494 Sold |
7,000 USD |
07/06/2024 | 07/06/2024 |
| Dittman Jennifer SR OFF |
14.00 USD |
1,042 Sold |
14,588 USD |
20/05/2024 | 20/05/2024 |
| Dittman Jennifer SR OFF |
14.04 USD |
23,578 Sold |
331,066 USD |
16/05/2024 | 16/05/2024 |
| Holles Natalie C. CEO |
12.18 USD |
20,222 Sold |
246,300 USD |
09/05/2024 | 09/05/2024 |